Clinical characteristics and survival of patients with advanced Merkel cell carcinoma treated with avelumab: analysis of a prospective German Merkel cell carcinoma registry
Jürgen Becker(Universitätsmedizin Göttingen), Selma Ugurel(Klinikum Bielefeld), Peter Möhr, Claudia Pföhler(Saarland University), Patrice Verpillat(Centre National de la Recherche Scientifique), Dirk Schadendorf(National Center for Tumor Diseases), Emmanuelle Boutmy(Merck KGaA, Darmstadt (Germany)), Friedegund Meier(National Center for Tumor Diseases), Stephan Grabbe(Goethe University Frankfurt), Fabian Ziller(Vivantes Klinikum), Martin Sachse(Institut Pasteur), Margarita Shlaen, Lisa Zimmer(The University of Sydney), Changbo Fu(Fudan University), Seyed Hamidreza Mahmoudpour(Johannes Gutenberg University Mainz), Anthony F. Milano, Ulrike Leiter(University of Tübingen), Rudolf Herbst(Helios Klinikum Erfurt), Steven J. Hoff(Merck KGaA, Darmstadt (Germany)), Christoffer Gebhardt(Universität Hamburg)
Cited by 0
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
|Science|2016|3.1k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k